Could cell-derived vesicles restart the ovaries? a new trial investigates

NCT ID NCT06202547

Completed Disease control Sponsor: Royan Institute Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This early-phase trial tests whether injecting tiny particles called extracellular vesicles, derived from bone marrow stem cells, directly into the ovary is safe for women with premature ovarian failure. The study includes 10 women aged 20–38 who have had no menstrual period for at least a year and high FSH levels. Researchers will monitor for side effects like abscess and measure hormone changes over 8 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: extracellular vesicles derived from bone marrow mesenchymal stromal cells
What this could lead to: If safe and effective, this approach could restore ovarian function and fertility in women with premature ovarian failure.
What could go wrong: This is an early, small trial focused on safety, not yet proof of effectiveness. The treatment may not restore ovarian function, and risks include infection or abscess from the injection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREMATURE OVARIAN FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

premature menopause primary ovarian failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREMATURE OVARIAN FAILURE

Contacts and locations

Show contact details

Locations

Royan Institute

Tehran, Tehran Province, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.